CD4 and neoplasm: Re-stimulation of splenocytes from vaccinated mice with class II HER2 peptides led to increased IFN-γ production, suggesting the critical role of the anti-HER2 CD4+ Th1 immune response in mediating reduction in tumor burden with enhanced survival benefit.